irinotecan has been researched along with entinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baylin, SB; Dobromilskaya, I; Easwaran, H; Huang, P; Poirier, JT; Rudin, CM; Topper, M; Vendetti, FP; Wrangle, J | 1 |
| Beyer, M; Hauzenberger, I; Heinzel, T; Kdimati, S; Krämer, OH; Lilla, S; Linnebacher, M; Maddocks, ODK; Marx, C; Marx-Blümel, L; Meyer, FB; Mullins, CS; Neri, F; Nunna, S; Piée-Staffa, A; Siniuk, K; Sonnemann, J; Thierbach, R; Wagner, T; Wang, ZQ; Westermann, M | 1 |
2 other study(ies) available for irinotecan and entinostat
| Article | Year |
|---|---|
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Methylation; Drug Evaluation, Preclinical; Epigenesis, Genetic; Female; Histones; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Pyridines | 2015 |
Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells.
Topics: Acetylation; Animals; Apoptosis; Benzamides; Colorectal Neoplasms; Humans; Irinotecan; Mice; Pyridines; Tumor Suppressor Protein p53 | 2021 |